MedBiome partners its advanced microbiome technology, called RapidAIM, for drug discovery, compound screening and development needs of pharmaceutical and biotech companies.
- focuses on screening compounds against individual microbiomes (human and animals)
- develops compound libraries that can reach the gut microbiome
- provides industry-leading functional metaproteomics, metagenomics and metabolomics approaches
- provides leading bioinformatics and software tools to assess the effects of drugs on the microbiome
For more information about MedBiome and interests in collaborations Please contact us at: